Dr. Christopher D'Avella, from the Penn Medicine’s Abramson Cancer Center, spoke with the Journal of Clinical Pathways regarding the collaboration between the Penn Medicine’s Abramson Cancer Center and Flatiron Health.
This collaboration utilized Flatiron Assist™ to enhance Penn Medicine’s Abramson Cancer Center's pathway program, aiming to streamline its integration into clinical workflows. Through a pilot study in thoracic oncology, they focused on improving the tool's speed, user interface, and introduced a hot button feature for quicker access to common treatment pathways.
Results, which were also presented at ASCO 2023, showed a significant increase in provider engagement with Flatiron Assist™, leading to improved efficiency with reduced session lengths and increased adoption rates.
Watch Dr. D'Avella’s interview with the Journal of Clinical Pathways below and keep reading to learn more about Flatiron’s partnership with Penn Medicine Abramson Cancer Center.
Learn more about our partnership with Penn Medicine Abramson Cancer Center
Flatiron Health has initiated a strategic collaboration with Penn Medicine’s Abramson Cancer Center to integrate its Flatiron Assist™ advanced cancer care insights into oncology care at the center, aiming to enhance guideline-concordant care, patient experiences, and health equity while reducing unnecessary spending.
Through this partnership, Flatiron Assist™ will prioritize evidence-based medicine, site-preferred pathways, and clinical research at the point of care, with goals to expand NCCN preferred guidelines across diseases and increase awareness of clinical trial opportunities, driving user adoption and satisfaction.
